Tirzepatide shows comparable efficacy and safety for obesity in adults ≥65 years versus younger adults

Managing obesity in older adults presents unique challenges, including polypharmacy, sarcopenia risk, and altered drug metabolism, making safety and tolerability paramount. While tirzepatide, a dual GLP-1R and GIPR agonist, is approved for weight management, specific data on its efficacy and safety in the ≥65 years demographic has been limited. This gap leaves clinicians and older individuals uncertain about its appropriate use, despite the clear link between increased BMI and worsening cardiometabolic risk factors in this population. Understanding how tirzepatide performs in this age group is crucial for expanding safe and effective treatment options.

This post hoc analysis evaluated the efficacy and safety of tirzepatide in adults aged ≥65 years with obesity. Researchers analyzed pooled data from several Phase 3 clinical trials: SURMOUNT-1 through -5 (including the SURMOUNT-1 3-year study), SURMOUNT-OSA, and SUMMIT. Efficacy outcomes, such as weight reduction and changes in cardiometabolic risk factors, were assessed at various time points depending on the original trial designs. Safety outcomes, including gastrointestinal tolerability, falls, fractures, and organ-related adverse events, were assessed throughout the treatment period in the pooled population. Results from participants aged ≥65 years were directly compared to those from participants aged <65 years.

Tirzepatide treatment was associated with clinically meaningful weight reduction and favorable treatment differences in cardiometabolic risk factors and quality-of-life measures in adults ≥65 years. These results were broadly comparable to those observed in adults <65 years. Specifically, no clinically meaningful differences in adverse event (AE) rates were observed between tirzepatide and placebo in older adults for key safety concerns. This included gastrointestinal tolerability, falls, fractures, depression outcomes, pancreatitis, and renal, hepatic, gallbladder, and biliary-related AEs. The analysis found no clinically relevant risks beyond those inherent to older age when comparing adults ≥65 years versus <65 years. This suggests that the dual GLP-1R/GIPR agonism of tirzepatide maintains a consistent safety and efficacy profile across different adult age groups. The study reinforces that older adults can achieve similar benefits without disproportionate adverse effects.

Tirzepatide treatment led to clinically meaningful weight reduction and improved cardiometabolic risk factors in adults ≥65 years, with results comparable to younger adults and no new safety signals.